BriaCell Therapeutics
BriaCell Therapeutics
BCT
TSX
6.33
CAD
-11.84%
About
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors.
The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyte’s immune PD-1 inhibitor, retifanlimab, in advanced breast cancer.
The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patient’s HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 12.3K |
| Three Month Average Volume | 232.3K |
| High Low | |
| Fifty-Two Week High | 9.80511 CAD |
| Fifty-Two Week Low | 0.75 CAD |
| Fifty-Two Week High Date | 01 Sep 2023 |
| Fifty-Two Week Low Date | 14 Aug 2024 |
| Price and Volume | |
| Current Price | 1.045 CAD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | 5.84% |
| Thirteen Week Relative Price Change | -56.47% |
| Twenty-Six Week Relative Price Change | -79.69% |
| Fifty-Two Week Relative Price Change | -90.55% |
| Year-to-Date Relative Price Change | -87.97% |
| Price Change | |
| One Day Price Change | 2.45% |
| Thirteen Week Price Change | -54.37% |
| Twenty-Six Week Price Change | -78.00% |
| Five Day Price Change | -12.18% |
| Fifty-Two Week Price Change | -89.12% |
| Year-to-Date Price Change | -86.60% |
| Month-to-Date Price Change | 1.46% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -0.3189 CAD |
| Book Value Per Share (Most Recent Quarter) | -0.50362 CAD |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.33706 CAD |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.52081 CAD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.94697 CAD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 CAD |
| Revenue Per Share (Trailing Twelve Months) | 0 CAD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 CAD |
| Dividend Per Share (Trailing Twelve Months) | 0 CAD |
| Dividend Per Share (5 Year) | -99999.99 CAD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.75382 CAD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.52802 CAD |
| Normalized (Last Fiscal Year) | -1.75382 CAD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.75382 CAD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.50695 CAD |
| Including Extraordinary Items (Last Fiscal Year) | -1.75382 CAD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.52802 CAD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.79418 CAD |
| Cash Per Share (Most Recent Quarter) | 0.079 CAD |
| Cash Flow Per Share (Last Fiscal Year) | -99999.99 CAD |
| Cash Flow Per Share (Trailing Twelve Months) | -99999.99 CAD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.59226 CAD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 134.03% |
| EPS Change (Trailing Twelve Months) | 66.88% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -1,262,530 |
| Net Debt (Last Fiscal Year) | -28,674,100 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 15 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -32,038,940 |
| Free Cash Flow (Trailing Twelve Months) | -41,841,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -58.22% |
| Return on Assets (Trailing Twelve Months) | -33.97% |
| Return on Assets (5 Year) | -59.37% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -619.75% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -211.36% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -60.61% |
| Return on Investment (Trailing Twelve Months) | -43.50% |
| Return on Investment (5 Year) | -63.11% |